COVID-19 Virtual Care at Home

Overview

This multicentre prospective cohort trial is designed to demonstrate effectiveness and efficiency of a virtual care model for the management of COVID-19 patients isolating at home. The investigators have reoriented existing technology and networks for this research project. The investigators are amplifying our existing virtual care platform VIRTUES, combining it with home monitoring of COVID-19 patients, to provide real-time evidence, harmonize data collection, and share data provincially to mitigate the impact of the rapid spread of the virus. The study will facilitate early detection of complications associated with the disease, treatment and management of COVID-19 patients at home. The research will be conducted provincially in Ontario. This initiative will provide evidence to inform clinical and health system management and public health response to COVID-19 patients isolating at home.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 4, 2022

Interventions

  • Other: Virtual Care at Home
    • Participants will have access to the VIRTUES platform for COVID-19 Virtual Care at Home

Arms, Groups and Cohorts

  • Other: COVID-19 Virtual Care at Home
    • VIRTUES COVID-19 Care at Home Platform The components of the platform will include: Vital sign monitoring, including O2 saturation with a home-based pulse oximeter, temperature and respiratory rate performed three times per day (a notification to do this will be sent from the app), with the option of doing assessments more frequently if needed. Study patients will be provided monitoring devices to collect this data. Symptom logs will be entered by the patients. Feedback to the patient by the local COVID-19 care team for any action: Two-way communication between the patient and the COVID-19 care team Ability for team members to see all prior notes in order to have continuity of care Reports of these interactions are transmitted to the patient’s health record Current information on COVID-19 as per the Public Health Agency of Canada

Clinical Trial Outcome Measures

Primary Measures

  • 14 Day Patient Satisfaction Questionnaire
    • Time Frame: 14 days
    • The primary outcome measure is patient satisfaction as measured from a patient satisfaction questionnaire at 14 days.

Secondary Measures

  • Emergency Department Visits
    • Time Frame: 14 days
    • The secondary outcome measures will include the number of patients that require an Emergency Department visits during the observation period of 14 days.
  • 14 Day EQ-5D-5L Scores
    • Time Frame: 14 days
    • The secondary outcome measures will include the health status measures of the EuroQuality of Life Five Dimensions (EQ-5D-5L) at 14 days. Scoring is Level 1 to 5 for each dimension; higher scores meaning worse health status.

Participating in This Clinical Trial

Inclusion Criteria

  • All COVID-19 positive patients of age 18 or above – Participant must communicate in English or French language – An email address and account Exclusion Criteria:

  • Unable or unwilling to provide informed consent

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Lawson Health Research Institute
  • Collaborator
    • Cardiac Arrhythmia Network of Canada
  • Provider of Information About this Clinical Study
    • Principal Investigator: Anthony Tang, Principal Investigator – Lawson Health Research Institute

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.